A Study Investigating the Renal Tolerability, Efficacy, and Safety of a CNI-free Versus a Standard Regimen in de Novo Heart Transplant (HTx) Recipients

NCT00862979 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

162

Enrollment

INDUSTRY

Sponsor class

Conditions

Heart Transplantation

Interventions

DRUG: Everolimus (EVR)
DRUG: cyclosporine A (CyA)
DRUG: tacrolimus (TAC)
DRUG: Enteric coated mycophenolate sodium (EC-MPS)
DRUG: mycophenolate mofetil (MMF)
DRUG: Corticosteroids

Sponsor

Novartis Pharmaceuticals